Olmesartan和Azilsartan蛋白尿和Intrarenal肾素-血管紧张素系统。

文章的细节

引用

复制到剪贴板

Takami T,冈田克也年代,齐藤Y, Y缝合,小崛H,西山

Olmesartan和Azilsartan蛋白尿和Intrarenal肾素-血管紧张素系统。

2018年世界J Res启扬;6 (1):7 - 10。

PubMed ID

29683146 (在PubMed

]

文摘

目的:Olmesartan和azilsartan降低血压更有效地比其他血管紧张素受体阻滞剂(arb)。arb另外降低尿白蛋白肌酐比值(UACR),尿白蛋白标记,和泌尿血管紧张肽原(u-AGT),一个intrarenal肾素-血管紧张素系统活动标志。我们检查了这些ARBs药物对血压的影响UACR, u-AGT在不受控制的高血压患者。ARBs传统治疗方法:不受控制的高血压患者,排除olmesartan azilsartan,超过8周被录取。我们随机将患者从arb olmesartan或azilsartan之前,跟从了24周。结果:收缩压(SBP)、舒张压(菲律宾),和中央收缩压(cSBP)明显降低在24周。UACR u-AGT也减少在两组24周。没有明显差异在SBP,类似cSBP, UACR或u-AGT之间的组织。因此,我们结合两组进行进一步的分析。结合后,SBP(160.5 + / - 16.4到139.6 + / - 15.6毫米汞柱,P < 0.0001),菲律宾(88.4 + / - 13.7到80.7 + / - 13.2毫米汞柱,P = 0.008), cSBP(167.4 + / - 20.8到146.6 + / - 24.6毫米汞柱,P < 0.0001), UACR(13.8至9.0毫克/克Cre, P = 0.0096),和u-AGT(4.13到2.32杯/ g Cre, P = 0.0074)显著降低在24周。 Patients with microalbuminuria (UACR >/= 30 mg/g Cre) had significantly greater DeltaUACR (-39.4 vs 0.27, P = 0.0024) and Deltau-AGT (-11.9 vs -0.61, P = 0.0235) than patients without microalbuminuria. The changes in u-AGT were significantly associated with changes in UACR (r = 0.411, P = 0.046); however, there was no significant relationship between the changes in u-AGT and those in SBP or DBP. Conclusion: Olmesartan and azilsartan decreased blood pressure, UACR, and u-AGT more than the other ARBs, and exerted depressor and renoprotective effects.

DrugBank数据引用了这篇文章

药物

Olmesartan